Nov 10-14, 2022

Topics

What's hot

View all perspectives

What's Hot

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.

Watch video →

Julian Segan JulianSegan

3 years 1 month ago

Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary https://t.co/B0eASeo8hG

Mike Putman EBRheum

3 years 1 month ago

Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless! It's not flashy but it winds up being the backbone/foundation for many subsequent studies Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD #ACR22 @RheumNow https://t.co/64z7DBFCnX

David Liew drdavidliew

3 years 1 month ago

GUSTO 1y follow-up (TCZ +IVMPx3 but no ongoing PNL in new GCA): initial 24w results disappointing (permanent visual loss x1) BUT follow-up at 2y: control overwhelmingly maintained in responders We need to keep asking: can we use less PNL in GCA? When? ABST0470 #ACR22 @RheumNow https://t.co/smyw2nykO5 https://t.co/d2at0pJlSB

https://twitter.com/drdavidliew/status/1325906973540315136

Catherine Sims, MD DrCassySims

3 years 1 month ago

Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow ⚠️safety data -Pancytopenia -Transaminitis -Dyslipidemia -Elevated CPK without #myositis -Avoid in pregnancy and GI strictures 🤰Stop JAKi at least one month prior to conception🤰

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 1 month ago

#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu

Bella Mehta bella_mehta

3 years 1 month ago

Abst#0001 MIRROR RCT at #ACR22 #plenary Pts with gout on #pegloticase and #gout sustained higher urate lowering response in pts cotreated with #MTX benefit beyond 6 months @rheumnow https://t.co/rTZ3fPaFJS

Catherine Sims, MD DrCassySims

3 years 1 month ago

Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow -Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI -5mg BID Xeljanz -Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo -Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt

Dr. John Cush RheumNow

3 years 1 month ago

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 1 month ago

#ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyelitis showed that patients had high level of pain and fatigue and low function. Important to assess for these and could be a treatment target @RheumNow https://t.co/451KrlJWZF

Dr. Rachel Tate uptoTate

3 years 1 month ago

mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse models. Further evaluation needs to be determined in humans, but interesting nonetheless. Abs 0004 #ACR22 @RheumNow https://t.co/RFokZqFQZp https://t.co/E7yxCPDGCd

mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activati…

Patricia Harkins DrTrishHarkins

3 years 1 month ago

🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC

Robert B Chao, MD doctorRBC

3 years 1 month ago

Excellent start to the first plenary session! MIRROR study - MTX coadministration with pegloticase for gout treatment - doubling of efficacy and 7x decrease in infusion reactions - less anti-PEG abs @RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO

Dr. Rachel Tate uptoTate

3 years 1 month ago

2022 IIM-assoc'd CA screening key takeaways Most common CA: lung, ovarian, colorectal, lymphoma, breast, & naso-pharyngeal High risk: DM, +anti-TIF1 gamma, +antiNXP2, >40 at IIM dx, severe/active dz, cutaneous necrosis, dysphagia Abs 0002 #ACR22 @RheumNow https://t.co/BhF1jJa8Oz https://t.co/oLVTLG34ck